Al-Khazraji Yamama, Muzammil Muhammad Ali, Javid Saman, Tangella Adarsh Vardhan, Gohil Namra Vinay, Saifullah Hanya, Kanagala Sai Gautham, Fariha Fnu, Muneer Asim, Ahmed Sumaira, Shariq Ali
Department of Medicine, Metropolitan Hospital Center, NY, USA.
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Int J Health Sci (Qassim). 2024 Sep-Oct;18(5):43-58.
The objective of this systematic review was to describe novel regimens and treatment strategies in neoadjuvant therapy for colorectal cancer (CRC). The aim was to summarize the current advancements in neoadjuvant chemotherapy (NACT) for CRC, including the use of cytotoxic drugs, targeted treatments, and immunotherapy. The analysis aimed to provide insights into the potential benefits and drawbacks of these novel approaches and highlight the need for further research to optimize NACT use in CRC and improve patient outcomes.
From October 20, 2023, to December 10, 2023, a comprehensive literature search was conducted across multiple databases, including PubMed, Ovid, Web of Science, the Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, Embase, and Scopus. Studies addressing the use of and treatment strategies for CRC and neoadjuvant therapies were included. Screening was conducted in two steps, initially by title and abstract and then by full-text articles. English-language articles were considered, while preprints, non-English publications, and articles published as grey literature were excluded from the study. A total of 85 studies were selected for further analysis after screening and filtering.
After filtering out duplicates and items that were irrelevant to our research query from the initial database search's 510 results, 397 unique articles were found. Eighty-five studies were chosen for additional analysis after the articles underwent two rounds of screening.
The review concluded that neoadjuvant therapy for CRC has evolved beyond conventional approaches and holds promise for improving patient outcomes. Future prospects for advancing neoadjuvant approaches are promising, with ongoing clinical trials investigating the refinement of strategies, identification of predictive biomarkers, and optimization of patient selection. The adoption of novel regimens, precision medicine, and immunotherapy offers opportunities to redefine treatment paradigms and enhance patient care in CRC.
本系统评价的目的是描述结直肠癌（CRC）新辅助治疗中的新型方案和治疗策略。旨在总结CRC新辅助化疗（NACT）的当前进展，包括细胞毒性药物、靶向治疗和免疫治疗的使用。该分析旨在深入了解这些新方法的潜在益处和缺点，并强调需要进一步研究以优化CRC中NACT的使用并改善患者预后。
2023年10月20日至2023年12月10日，在多个数据库中进行了全面的文献检索，包括PubMed、Ovid、科学网、Cochrane图书馆、护理及相关健康文献累积索引、Embase和Scopus。纳入了涉及CRC使用和治疗策略以及新辅助治疗的研究。筛选分两步进行，首先通过标题和摘要，然后通过全文文章。考虑英文文章，而预印本、非英文出版物和作为灰色文献发表的文章被排除在研究之外。经过筛选和过滤，共选择了85项研究进行进一步分析。
在从初始数据库搜索的510条结果中筛选出重复项和与我们的研究问题无关的条目后，发现了397篇独特的文章。在这些文章经过两轮筛选后，选择了85项研究进行进一步分析。
该综述得出结论，CRC的新辅助治疗已超越传统方法，有望改善患者预后。推进新辅助治疗方法的未来前景广阔，正在进行的临床试验正在研究策略的优化、预测生物标志物的识别和患者选择的优化。采用新型方案、精准医学和免疫治疗为重新定义治疗模式和加强CRC患者护理提供了机会。
